The finalisation of ICH E6(R3) marks a clear shift in how quality, oversight and accountability are expected to be managed across clinical development. Although ICH E6(R3) is often discussed in the context of large, late-stage programmes, its implications for early-phase trials are equally significant, particularly where emerging data inform decisions on dosing, cohort progression or protocol adaptation.
Rather than adding procedural burden, E6(R3) reframes quality as a risk-proportionate activity focused on what is critical to participant safety and data reliability, not as a fixed set of procedures applied uniformly across all studies. Below are seven practical implications that sponsors should consider when designing and overseeing Phase I studies.
1. Risk‑Proportionate Quality Management in Phase I
What changed: E6(R3) explicitly emphasises identifying and managing risks that are critical to participant safety and data reliability, rather than applying uniform quality controls across all trial activities.
Impact on Phase I: In early-phase studies, this means quality management should be built into trial design and the conduct of critical trial processes. Particular attention should be given to activities that affect participant safety, data reliability and early development decisions, such as dose escalation, cohort progression and go/no-go decisions. Oversight and monitoring should be tailored to these risks rather than spread evenly across all processes.
Sponsors should review: Have we clearly identified which study activities are critical to participant safety and early decision‑making, and aligned monitoring and oversight accordingly?
2. Enhanced Sponsor Oversight Expectations
What changed: E6(R3) clarifies that sponsors retain full accountability for trial quality and participant protection, even when activities are delegated to CROs or other service providers.
Impact on Phase I: In early‑phase development, oversight must be structured around the processes that matter most for participant safety, data reliability and early development decisions. Sponsors are expected to understand how key risks are managed in practice, including how oversight responsibilities are organised across CROs and other service providers. Oversight should therefore provide meaningful insight into critical processes, how risks are managed day to day and whether issues are escalated in a timely manner.
Sponsors should review: Do we have sufficient insight into how key risks are managed day to day, including how oversight is coordinated across CROs and other service providers, and is this oversight structured around decision‑critical activities rather than organisational boundaries?
3. Modernised Data Governance and Digital Systems
What changed: E6(R3) explicitly recognises electronic systems as central to data integrity, traceability and quality management.
Impact on Phase I: Early‑phase studies generate complex, high‑frequency data that often inform near‑real‑time decisions. Data systems must therefore support timely review, clear audit trails and integration across sources, rather than functioning solely as repositories for final datasets.
Sponsors should review: Do our data systems enable timely review of decision-critical data, and are responsibilities, access controls, audit trails and data flows clearly defined across all contributing systems and service providers?
4. Documentation and Traceability Standards
What changed: E6(R3) uses the concept of essential records, including documents, data and relevant metadata, to support evaluation of trial conduct, actions taken during the trial and the reliability of trial results.
Impact on Phase I: Phase I studies often involve adaptations based on emerging data. Essential records should therefore make clear not only what decisions were made, but also the evidence, risk assessment and scientific rationale that supported them at the time.
Sponsors should review: Can we clearly demonstrate how key development decisions were supported by data, risk assessment and scientific rationale?
5. Service Provider Qualification and Oversight
What changed: E6(R3) reinforces that delegation of activities does not transfer responsibility. Sponsors remain accountable for transferred sponsor activities, while investigators retain oversight of delegated activities under their responsibility.
Impact on Phase I: Early‑phase trials often rely on specialised service providers for assays, biomarkers or modelling that directly influence development decisions. Oversight should therefore focus on how service provider outputs contribute to decision‑making, not only on contractual compliance.
Sponsors should review: Are service providers selected, qualified and overseen based on their role in critical study outcomes and early development decisions?
6. Decentralised and Hybrid Design Considerations
What changed: E6(R3) accommodates innovative trial approaches, provided risks to participants and data integrity are appropriately managed.
Impact on Phase I: While decentralised, hybrid or distributed elements can improve efficiency or feasibility, they may also introduce variability in data collection and oversight. In early‑phase studies, such elements should be implemented only where they clearly support study objectives and risk control.
Sponsors should review: Do decentralised, hybrid or distributed elements clearly support the study objectives, and have responsibilities, data flows and quality measures been adapted accordingly?
7. Inspection Readiness in a Risk‑Based Environment
What changed: E6(R3) places greater emphasis on essential records and risk-based quality management to support evaluation of trial conduct, actions taken and the reliability of trial results.
Impact on Phase I: Inspection readiness is therefore not only about whether records are complete, but whether they allow key decisions to be understood. In Phase I, this is particularly relevant where emerging data inform dose escalation, cohort progression, stopping decisions or protocol adaptations.
Sponsors should review: Can we clearly demonstrate how risk management, oversight and emerging data informed key Phase I decisions?
From compliance to decision support
ICH E6(R3) reinforces that early‑phase trials are not exempt from quality expectations, but they do require proportionate and thoughtful application. For sponsors, the challenge is not to do more, but to focus on what matters most.
When quality management is aligned with scientific and development objectives, early-phase studies can support both compliance and better-informed development decisions.
